NIH Shifts Meeting to Virtual with Time Adjustment
Published Date: 8/15/2025
Notice
Summary
The NIH Council of Councils meeting on September 11-12, 2025, has switched to fully virtual and moved to a new online location. The start and end times on September 12 have shifted slightly, and part of the meeting will be closed to the public. This update affects attendees and anyone following NIH decisions but doesn’t change any funding or deadlines.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
NIH Council meeting goes fully virtual
The NIH Council of Councils meeting on September 11–12, 2025 is now fully virtual. The meeting runs from September 11, 2025 at 10:00 a.m. through September 12, 2025 (start time on Sept. 12 changed to 10:00 a.m. and the end time changed to 2:15 p.m.), lists the location as National Institutes of Health, 1 Center Drive, Bethesda, MD 20892, and is partially closed to the public. This change does not alter any funding or deadlines.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13802 — Government Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
The National Institutes of Health is offering special mouse strains that help study a rare heart rhythm disorder called CPVT. These mice let scientists explore how a key heart gene works and test new gene therapies. Researchers interested in this tool can access it now—no patents, just pure science ready to speed up discoveries!
2026-13612 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review and decide on important health research grant applications. These meetings keep sensitive info private to protect personal and commercial secrets. Researchers applying for grants and the public can expect no changes in funding timing or amounts, just careful, confidential reviews.
2026-13480 — Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
2026-13479 — Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
2026-13337 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on July 24, 2026, to review and evaluate important grant applications related to cancer, imaging, eye diseases, and reproductive health. These meetings protect private info and trade secrets, so they’re not open to the public. Researchers and organizations applying for grants should note the dates as these reviews impact funding decisions.
2026-13311 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review grant applications and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants or contracts should watch these dates closely, as funding decisions could impact their projects and budgets.
Previous / Next Documents
Previous: 2025-15556 — Revocation of Authorization of Emergency Use of In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19; Availability
The FDA is ending the emergency approval for LumiraDx’s COVID-19 test because the company asked them to. This means the test can no longer be used for quick COVID-19 diagnosis. If you use or sell this test, you’ll need to stop soon, but no extra costs or penalties are mentioned.
Next: 2025-15559 — Notice of OFAC Sanctions Actions
The U.S. Treasury’s OFAC just added new people to its blacklist, meaning their money and property in the U.S. are frozen. Americans can’t do business with these folks anymore, so watch out for these new restrictions. This move helps keep bad actors from using the U.S. financial system, and it’s effective immediately!